WHO ICTRP trial
Nimotuzumab- Head and neck cancer
RPCEC00000089 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Not Recruiting
Key facts
| Trial ID | RPCEC00000089 |
|---|---|
| Public title | Nimotuzumab- Head and neck cancer |
| Scientific title | Using the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages. |
| Primary sponsor | Center of Molecular Immunology(CIM) |
| Secondary sponsors | Not applicable |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | Cuba |
| Conditions | Squamous cell carcinoma of head and neck in advanced stages. |
| Interventions | Treatment schemes: 1.Schedule A:Nimotuzumab + RT 2.Schedule B:Nimotuzumab + RT + CT,concurrent 3.Schedule C:Nimotuzumab + RT + CT,sequential 4.Scheme D:Monotherapy with Nimotuzumab 5.Scheme E: Nimotuzumab + CT Nimotuzumab Indication: 200 mg… |
| Registration date | Oct 22, 2009 |
| Target size | Inclusion of 3 years. |
| Secondary IDs | IIC RD-EC0113 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: